Sahel Reporter

Accra has drawn a line in the sand. In a move that signals a decisive shift in how African nations approach foreign health funding, Ghana rejected a proposed health agreement with the United States that would have delivered roughly $109 million over five years. The overall package was valued at about $300 million when complementary contributions from Ghana are included. The decision, confirmed by President John Dramani Mahama during an appearance at the Council on Foreign Relations in New York on September 25, has ignited a broader conversation about health sovereignty across the continent.

Mahama’s words cut straight to the heart of the matter: “Who takes the medical records of another country?”

What the proposed deal actually contained

According to the Ghanaian leader, the draft agreement would have required Ghana to share pathogen profiles and medical data with the United States. He also stated that the text imposed a counterpart funding obligation on Ghana and included provisions affecting oversight of medical products entering the country. For Mahama, these conditions were simply “humiliating.”

But the story deserves a closer look beyond the headline-grabbing quote.

Ghana did not walk away from $100 million merely because it came from Washington. The sticking point was the strings attached to the money.

The Associated Press reported in May that the draft agreement, with a total value of approximately $300 million, would have provided Ghana with about $109 million over five years. Arnold Kavaarpuo, executive director of Ghana’s Data Protection Commission and a participant in the negotiations, indicated that certain provisions would have allowed access to sensitive health data under circumstances that could potentially identify individuals. In his view, the scope of that access went far beyond what is typically necessary.

The BMJ also reported that the Ghanaian draft envisioned access to health data and pathogens for 16 American companies. The journal noted, however, that several clauses in the new U.S. health agreements remain difficult to scrutinize publicly, as not all negotiated texts have been made available.

A nuance is therefore essential: it would be excessive to claim that the United States was demanding unrestricted access to “all Ghanaians’ medical records.” What is documented, however, are Ghanaian concerns about the extent of access to health data and pathogen information.

Why pathogen data and health records matter so much

Behind medical files lies a genuine question of power.

Health data reveals which diseases are circulating, where they are spreading, which populations are most exposed, and how epidemics are evolving.

Pathogen data can also carry considerable scientific value. It can contribute to research on vaccines, treatments, and surveillance of emerging outbreaks.

This is precisely what fuels concerns among several African governments.

In February 2026, Jean Kaseya, director general of the Africa Centres for Disease Control and Prevention (Africa CDC), had already expressed serious concerns about provisions related to data and pathogen sharing in the new U.S. health agreements. Reuters reported at the time that some agreements required rapid sharing of sensitive data without guaranteeing African countries access to treatments or vaccines that might result from that information.

Ghana is therefore not an isolated case.

Accra’s push to end reliance on foreign aid

The rejection also unfolds in a particular context.

Since the suspension of a large portion of U.S. aid programs, Ghana has been seeking to reduce its dependence on external funding. In February 2025, the Ghanaian presidency estimated the shortfall caused by the suspension of USAID funding at $156 million, with $78.2 million directly affecting essential health programs.

The Mahama government is now championing the idea of “health sovereignty.”

This direction was reinforced in September with the launch of the report A Sovereign Future for Health, presented as part of the Accra Reset initiative. The document proposes reducing Southern countries’ dependence on external funding and strengthening their own health systems.

Accra’s message is relatively clear: Ghana wants to continue working with foreign partners, but on the basis of agreements it considers more balanced.

Another friction point: control over medicines

The other element revealed by Mahama is particularly sensitive.

According to the president, the draft agreement would have exempted certain medicines and medical products provided under the program from oversight by Ghana’s Food and Drugs Authority (FDA).

This claim has not been publicly confirmed in detail by the U.S. government, which, when questioned by the Associated Press, said it does not comment on the details of bilateral negotiations.

But if this provision indeed reflected the text presented to the Ghanaian government, it explains part of Accra’s firmness: for the authorities, health funding should not lead to reducing the national regulator’s ability to oversee medical products used on its territory.

Washington’s response

Washington has not publicly detailed the contested clauses.

A U.S. State Department spokesperson said the United States does not disclose details of bilateral negotiations, while affirming that Washington continues to seek ways to strengthen its partnership with Ghana.

The absence of a full public release of the text makes it impossible to settle certain essential questions.

What data would have been exactly accessible?

To which American companies or institutions?

Under what circumstances could individuals have been identified?

How long would data have been retained?

What legal safeguards would have protected Ghanaian patients?

On these points, public information remains incomplete.

A debate that reaches far beyond Ghana

The real issue in this affair may lie precisely there.

For decades, many African health systems have depended on funding, medicines, equipment, and programs from abroad. These partnerships have saved lives and helped combat major diseases.

But the digital transformation of health is now changing the nature of cooperation.

Aid is no longer just about money, medicines, or equipment. It can also provide access to a strategic resource: data.

And Ghana has just reminded the world that it intends to retain control over that resource.

John Mahama says his government rejected the draft after review by the Ministry of Health and its passage through Cabinet. He also says the decision had the support of the entire government and that the rejection was decided very quickly.

Ghana will now have to demonstrate that it can fill the abandoned funding gap without compromising its health programs.

But for Accra, the choice seems deliberate:

better to seek other partners than to conclude an agreement the government considers incompatible with health sovereignty and the protection of Ghanaians’ data.

The question Ghana now poses to its foreign partners is simple:

When Africa receives aid to care for its populations, must it also surrender control over information about those populations?

The debate is probably only beginning.

By Anne Nkeng — Société et culture